dw a 2114r profile

ID Source	ID
PubMed CID	72031
SCHEMBL ID	1650088
MeSH ID	M0163878

Synonym
(-)-cis-((r)-2-(aminomethyl)pyrrolidine)(1,1-cyclobutanedicarboxylato)platinum
dwa 2114r
dwa 2114
dwa2114r
platinum, (1,1-cyclobutanedi(carboxylato-kappao)(2-))(2-pyrrolidinemethanamine-kappan1,kappan2)-, (sp-4-3(1r-(cis))-
miboplatin [inn]
platinum, (1,1-cyclobutanedicarboxylato(2-))(2-pyrrolidinemethanamine-nalpha,n1)-, (sp-4-3-(1r-cis))-
dw a 2114r
(-)-(r)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)platinum(ii) hydrate
1,1-cyclobutanedicarboxylato(2-aminomethylpyrrolidine)platinum(ii)
platinum, (1,1-cyclobutanedi(carboxylato-kappao)(2-))((1r,2r)-2-pyrrolidinemethanamine-kappan1,kappan2)-, (sp-4-3)-
2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylatato)platinum ii
platinum, (1,1-cyclobutanedicarboxylato(2-))(2-pyrrolidinemethanamine-n(sup alpha),n(sup 1))-,(sp-4-3-(1r-cis))-, monohydrate
ccris 5235
06241b5s4p ,
unii-06241b5s4p
miboplatin [mart.]
miboplatin hydrate [jan]
miboplatin [mi]
SCHEMBL1650088
Q27116714
DTXSID70908584
platinum(2+) cyclobutane-1,1-dicarboxylate--1-(pyrrolidin-2-yl)methanamine (1/1/1)

Excerpt	Relevance	Reference
"(-)-(R)-2-Aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato++ +)platinum(II) monohydrate (DWA2114R), cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP) were compared for their antitumor effects and nephrotoxicity-inducing activities at the same dosage (1/8, 1/4, 1/3, 1/2, 2/3 or 3/4 of the LD10 or LD10) on the basis of their intravenous lethal doses in mice."	( Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP) Akamatsu, K; Endo, K; Koizumi, K; Koizumi, M; Matsumoto, T; Mitsui, H; Morikawa, K, )	0.13
" Increases in exposure time of K562 cells to DWA2114R resulted in progressive shifting of the dose-response curve to the left, or more effective cell growth inhibition of the cells."	( Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin. Kobayashi, H; Miyachi, H; Ogawa, T; Takemura, Y, 1991)	0.28

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
platinum coordination entity
pyrrolidines	Any of a class of heterocyclic amines having a saturated five-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	11 (23.40)	18.7374
1990's	36 (76.60)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	6 (11.32%)	5.53%
Reviews	4 (7.55%)	6.00%
Case Studies	1 (1.89%)	4.05%
Observational	0 (0.00%)	0.25%
Other	42 (79.25%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.38	2	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	1.98	1	0	mitomycin	alkylating agent; antineoplastic agent
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	1.98	1	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	2.67	3	0	elemental platinum; nickel group element atom; platinum group metal atom
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.39	2	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
deuterium oxide Deuterium Oxide: The isotopic compound of hydrogen of mass 2 (deuterium) with oxygen. (From Grant & Hackh's Chemical Dictionary, 5th ed) It is used to study mechanisms and rates of chemical or nuclear reactions, as well as biological processes.	2	1	0	deuterated compound; water	NMR solvent
etoposide [no description available]	2.68	3	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
vindesine Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).	1.98	1	0	methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	1.98	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
irinotecan [no description available]	1.99	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) [no description available]	3.08	1	0
carboplatin [no description available]	10.3	47	6
aclarubicin Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.	1.98	1	0	aminoglycoside; anthracycline; methyl ester; phenols; polyketide; tetracenequinones; trisaccharide derivative; zwitterion	antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
picibanil Picibanil: A lyophilized preparation of a low-virulence strain (SU) of Streptococcus pyogenes (S. hemolyticus), inactivated by heating with penicillin G. It has been proposed as a noncytotoxic antineoplastic agent because of its immune system-stimulating activity.	1.98	1	0	penicillinate anion
didimethylsulfoxide dichloroplatinum(ii) [no description available]	1.97	1	0
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	1.98	1	0	organic cation; xanthene dye	fluorochrome
peplomycin Peplomycin: An antineoplastic agent derived from BLEOMYCIN.	1.98	1	0	glycopeptide
enloplatin enloplatin: structure given in first source	3.08	1	0
nk 121 NK 121: structure given in first source	7.74	12	2
nedaplatin nedaplatin: structure given in first source	8.67	17	3
guanosine monophosphate Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase.	2	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	biomarker; Escherichia coli metabolite; metabolite; mouse metabolite
guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose.	1.97	1	0	guanosines; purines D-ribonucleoside	fundamental metabolite
deoxydiguanosine diphosphosphate 5'-d(pGpG)-3' : A single-stranded DNA oligonucleotide comprising two 2'-deoxyguanosine residues connected by a 3'->5 linkage and with a phosphoric group at the 5'-terminus.	2	1	0	5'-phospho-(3'->5')-dinucleotide; single-stranded DNA oligonucleotide	Mycoplasma genitalium metabolite

Condition	Relationship Strength	Studies	Trials
Adenocarcinoma, Basal Cell [description not available]	2.67	3	0
Cancer of Colon [description not available]	2.67	3	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.67	3	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.67	3	0
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	1.98	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1	0
Metastase [description not available]	1.98	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	1.98	1	0
Cancer of Ovary [description not available]	6.7	8	3
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	6.7	8	3
Cystadenocarcinoma, Serous A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)	1.98	1	0
Cancer of Stomach [description not available]	1.98	1	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	1.98	1	0
Carcinoma, Non-Small Cell Lung [description not available]	5.72	2	2
Cancer of Lung [description not available]	6.56	6	2
Cancer of Prostate [description not available]	4.97	3	1
Cancer of Testis [description not available]	4.97	3	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	5.72	2	2
Lung Neoplasms Tumors or cancer of the LUNG.	6.56	6	2
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	4.97	3	1
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	4.97	3	1
Malignant Melanoma [description not available]	1.98	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	1.98	1	0
Anemia, Fanconi [description not available]	1.98	1	0
Kaposi Disease [description not available]	1.98	1	0
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	1.98	1	0
Xeroderma Pigmentosum A rare, pigmentary, and atrophic autosomal recessive disease. It is manifested as an extreme photosensitivity to ULTRAVIOLET RAYS as the result of a deficiency in the enzyme that permits excisional repair of ultraviolet-damaged DNA.	1.98	1	0
Teratocarcinoma A malignant neoplasm consisting of elements of teratoma with those of embryonal carcinoma or choriocarcinoma, or both. It occurs most often in the testis. (Dorland, 27th ed)	1.99	1	0
Carcinoma, Oat Cell [description not available]	4.68	2	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	4.68	2	1
Leukemia L 1210 [description not available]	2.67	3	0
Benign Neoplasms [description not available]	3.58	3	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.58	3	0
Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)	2.38	2	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.98	1	0
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	4.62	3	2
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	4.33	2	2
Leukemia, Lymphocytic, T Cell [description not available]	1.98	1	0
Leukemia, T-Cell A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.	1.98	1	0
Leukocytopenia [description not available]	3.07	5	0
Emesis [description not available]	3.77	2	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.07	5	0
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	3.77	2	1
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.38	2	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	1.98	1	0
Breast Cancer [description not available]	3.36	1	1
Breast Neoplasms Tumors or cancer of the human BREAST.	3.36	1	1
EHS Tumor [description not available]	1.98	1	0
Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed)	2.38	2	0
Leucocythaemia [description not available]	1.97	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1.97	1	0
Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed)	1.97	1	0
Experimental Neoplasms [description not available]	2.38	2	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	3.36	1	1
Dysmyelopoietic Syndromes [description not available]	3.36	1	1
Granulocytic Leukemia, Chronic [description not available]	3.36	1	1
Acute Myelogenous Leukemia [description not available]	3.36	1	1
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	3.36	1	1
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	3.36	1	1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	3.36	1	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	3.36	1	1
Carcinoma, Epidermoid [description not available]	2.38	2	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	2.38	2	0
Cancer of the Uterus [description not available]	1.97	1	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	1.97	1	0
Cancer of Pharynx [description not available]	1.97	1	0
Pharyngeal Neoplasms Tumors or cancer of the PHARYNX.	1.97	1	0
Sarcoma 180 An experimental sarcoma of mice.	1.97	1	0
Thrombopenia [description not available]	2.66	3	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	2.66	3	0
Cancer of Cervix [description not available]	3.36	1	1
Female Genital Neoplasms [description not available]	3.36	1	1
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	3.36	1	1
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	3.36	1	1
Bladder Cancer [description not available]	1.97	1	0
Genito-urinary Cancer [description not available]	1.97	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	1.97	1	0
Urogenital Neoplasms Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.	1.97	1	0
Weight Reduction [description not available]	1.97	1	0
Weight Loss Decrease in existing BODY WEIGHT.	1.97	1	0

dw a 2114r

Cross-References

Synonyms (23)

Research Excerpts

Dosage Studied

Roles (1)

Drug Classes (2)

Research

Studies (47)

Market Indicators

Research Demand Index: 10.70

Study Types

dw a 2114r

Cross-References

Synonyms (23)

Research Excerpts

Dosage Studied

Roles (1)

Drug Classes (2)

Research

Studies (47)

Market Indicators

Research Demand Index: 10.70

Study Types

Related Drugs (23)

Related Conditions (80)